Berenberg Bank Reaffirms “Buy” Rating for AstraZeneca plc (AZN)
Berenberg Bank reiterated their buy rating on shares of AstraZeneca plc (LON:AZN) in a report released on Monday. The brokerage currently has a GBX 5,500 ($71.03) target price on the biopharmaceutical company’s stock.
A number of other research firms also recently commented on AZN. Morgan Stanley reiterated an overweight rating and set a GBX 5,600 ($72.32) target price on shares of AstraZeneca plc in a research report on Friday, June 23rd. UBS AG set a GBX 5,150 ($66.51) target price on AstraZeneca plc and gave the stock a neutral rating in a research report on Tuesday, June 27th. Shore Capital reiterated a hold rating on shares of AstraZeneca plc in a research report on Wednesday, June 21st. Barclays PLC reiterated an overweight rating and set a GBX 6,000 ($77.49) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, J P Morgan Chase & Co reiterated a neutral rating on shares of AstraZeneca plc in a research report on Monday, June 5th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of GBX 5,022.91 ($64.87).
AstraZeneca plc (AZN) opened at 4862.00 on Monday. The firm’s market capitalization is GBX 61.55 billion. The company has a 50-day moving average price of GBX 4,560.14 and a 200 day moving average price of GBX 4,882.27. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00.
TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/14/berenberg-bank-reaffirms-buy-rating-for-astrazeneca-plc-azn.html.
The company also recently declared a dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, August 10th were paid a dividend of GBX 68.90 ($0.89) per share. The ex-dividend date was Thursday, August 10th. This represents a yield of 1.35%.
In other news, insider Nazneen Rahman purchased 39 shares of the company’s stock in a transaction on Thursday, July 27th. The stock was bought at an average cost of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.